The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and ...
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...
"Gilead and LEO Pharma link on programmes for inflammatory conditions" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has ...
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.